All Outputs (2)

Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease (2008)
Journal Article
Wakil, A., Rigby, A. S., Clark, A. L., Kallvikbacka-Bennett, A., & Atkin, S. L. (2008). Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. European journal of endocrinology, 159(4), R11-R14. https://doi.org/10.1530/eje-08-0365

OBJECTIVE: Recent trials suggest that using ergot-derived dopamine agonists such as cabergoline in the treatment of Parkinson's disease is associated with an increased risk of valvular heart disease. However, the dose of cabergoline used to treat hyp... Read More about Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease.

The timing of development and subsequent clinical course of heart failure after a myocardial infarction (2008)
Journal Article
Torabi, A., Cleland, J. G., Khan, N. K., Loh, P. H., Clark, A. L., Alamgir, F., …Goode, K. (2008). The timing of development and subsequent clinical course of heart failure after a myocardial infarction. European Heart Journal, 29(7), 859-870. https://doi.org/10.1093/eurheartj/ehn096

Aims: Myocardial infarction (MI) is a common cause of heart failure (HF), which may develop early and persist or resolve, or develop late. The cumulative incidence, persistence, and resolution of HF after MI are poorly described. The aim of this stud... Read More about The timing of development and subsequent clinical course of heart failure after a myocardial infarction.